Paradigm Therapeutics Inc.

About Paradigm Therapeutics Inc.

Paradigm Therapeutics is a biopharmaceutical company dedicated to improving the lives of patients with serious, life-threatening diseases through the discovery, development, and delivery of innovative therapies, with a focus on rare diseases such as Epidermolysis Bullosa (EB).

Products & Services

Zorblisa™ (SD-101):A proprietary topical therapy developed for the treatment of Epidermolysis Bullosa (EB), designed to be administered across the entire body to address wound healing, wound burden, and infections across all EB subtypes.

Specialties

Rare disease therapies Epidermolysis Bullosa (EB) treatment Topical therapy development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Equity Investment T: - FT: Equity Investment	A: 12600000 MR: - FA: 12.6 million FAN: 12600000	D: 2025-06-18 FD: 2025-06-18	1 investors
2	RT: Investment T: - FT: Investment	A: 12500000 MR: - FA: $12.5 Million FAN: 12500000	D: 2025-05-06 FD: 2025-05-06	1 investors

Equity Investment Latest

2025-06-18

$12.6M

1 investor (Pro only)

Investment 2025-05-06

$12.5M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Robert Ryan

Founder and Chief Executive Officer

D

Dr. Ron Nardi

Executive VP Development

M

Michael Zimmer

Chief Financial Officer

W

Willistine Lenon

Executive VP Clinical Operations

S

Steve Cole

Head of Business Development

C

Christopher Ryan

Executive Director, Regulatory Affairs and Operations

View 3 more team members with Pro

Unlock Full Team Directory

Recent News